CTx1000 ALS Trial: First Patient Dosed in Gene Therapy Study Targeting TDP-43
Sydney, Australia – Celosia Therapeutics announced today the first patient has been dosed in its Phase 1b KOANEWA clinical trial, marking a significant step forward in … Read more